All In MedTech

Device Trial Radar · NCT06629506

MicroMatrix® Flex in Tunneling Wounds

Prospective Evaluation of MicroMatrix® Flex in Wounds Complicated by Tunneling and Undermining

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Dec 12, 2024

Primary completion

Aug 31, 2025

Study completion Aug 31, 2025

Sponsor

Lead sponsor
Integra LifeSciences CorporationPublic (IART)
Sponsor type
Industry
First posted
Oct 8, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and performance of MicroMatrix® Flex in subjects with wounds complicated by tunneling and/or undermining features.

Conditions

  • Pressure Injury
  • Venous Ulcer
  • Necrotizing Soft Tissue Infection
  • Diabetic Ulcers
  • Draining Wound

Interventions

  • MicroMatrix® FlexDevice

    MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.

  • MicroMatrix® UBM ParticulateDevice

    MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.

  • Cytal® Wound Matrix 2-LayerDevice

    Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative rate of closure of a tunneling or undermining featureTime frame: At 12 weeks or skin graft visit

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • MedStar Health Research Institute Inc.

    Washington D.C., District of Columbia

  • Northwell Comprehensive Wound Healing Center

    Lake Success, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.